🇺🇸 FDA
Patent

US 12312348

RET inhibitors, pharmaceutical compositions and uses thereof

granted A61PA61P1/12A61P29/00

Quick answer

US patent 12312348 (RET inhibitors, pharmaceutical compositions and uses thereof) held by SUNSHINE LAKE PHARMA CO., LTD. expires Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
SUNSHINE LAKE PHARMA CO., LTD.
Grant date
Tue May 27 2025 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon May 22 2045 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61P, A61P1/12, A61P29/00, A61P35/00